Oramed’s Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.

JERUSALEM, Israel, December 21, 2009 /PRNewswire-FirstCall via COMTEX/ — Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer
of alternative drug delivery systems, announced today that Dr Roy Eldor will
present an overview of the clinical development of Oramed’s Oral Insulin
capsule. Dr. Eldor is the principal investigator for all […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society’s Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug
delivery systems, announced today that its poster entitled “A novel GLP-1
analog delivered orally reduces postprandial glucose excursions in a porcine
model,” has been accepted for presentation at the Diabetes Technology
Society’s Ninth Annual […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society’s Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug
delivery systems, announced today that its poster entitled “A novel GLP-1
analog delivered orally reduces postprandial glucose excursions in a porcine
model,” has been accepted for presentation at the […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP-1 Analog Aimed at Improving Glycemic Control in Adults with Type 2 Diabetes
JERUSALEM, September 9 /PRNewswire-FirstCall/ — Oramed Pharmaceticals,
Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced
today […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference

JERUSALEM, September 3 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals
Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of alternative
drug delivery systems, announced today that Nadav Kidron, its Chief Executive
Officer, is scheduled to present at the Rodman & Renshaw’s 11th Annual
Healthcare Conference on Friday September 11, […]

Categories: Press Releases|Tags: |

Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award

JERUSALEM, August 25 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery
systems, today announced that it is the recipient of the 2009 Frost &
Sullivan European Oral Drug Delivery Technology Innovation Award.
Oramed Pharmaceuticals is developing […]

Categories: Press Releases|Tags: |

Oramed’s Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England

JERUSALEM, August 18 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals,
Inc. (OTC: ORMP) (http://www.oramed.com), a developer of alternative drug
delivery systems, announced today that Oramed’s Chief Scientific Officer,
Miriam Kidron, Ph.D. was chosen to present an overview of the clinical
development of Oramed’s Oral Insulin capsule at Science@BPC […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

JERUSALEM, Israel, August 4 /PRNewswire-FirstCall/ — Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer
of oral delivery systems, today reported that its wholly owned Israeli
subsidiary, Oramed Ltd., was awarded a government grant amounting to a total
net amount of NIS 3.1 million ($828,000), […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ — Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer
of alternative drug delivery systems, today reported positive results from a
Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic
patients. The completion of this study […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals, Inc.
(OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery
systems, announced that Oramed was chosen to present at the 8th National Life
Science & Technology Week ILSI-BIOMED Conference, Israel 2009. The
presentation will be given by Mr. Nadav […]

Categories: Press Releases|Tags: |